KRAS and cancer: In line with this, clinical trials confirmed that patients with KRAS-mutant cancers generally have a poor response to the first generation of EGFR inhibitors, such as erlotinib and gefitinib, and the presence of KRAS mutations is used as a biomarker to exclude patients for EGFR inhibitor therapy (7, 8, 69).